Pay in 4 interest-free payments of $5.18 Learn more
Ships within 48 hours · Estimated delivery Aug 26 - Aug 31
Neither is universally better
Farxiga/Forxiga (dapagliflozin) Disease area(s): Metabolic diseases Manufacturer(s): AstraZeneca 2024 Sales (USD): $7.72 billion Why it sold so well: In 2024, AstraZenecas Farxiga achieved robust sales growth, with revenues increasing by 21% year-over-year to $1.9 billion in the fourth quarter alone and by 28% compared to 2023, making it the companys top seller in 2024
In the 6-OHDA rat model of PD, semaglutide normalized IRS-1 phosphorylation [130], and levels of pIRS-1 were increased by the GLP-1 receptor agonist exendin-4 and a dual GLP-1/GIP agonist, DA-CH5 [45, 131]
This is partly due to tirzepatide's mechanism of action as a double agonist, permitting it to assert a more significant decrease in hyperglycemia as compared to glucagon-like peptide (GLP-1) agonists on their own [8]
10.3389/fphar.2022.936677 148 ShiX.XieX.SunY.HeH.HuangH.LiuY.et al (2020)
Serious adverse events like pancreatitis or severe allergic reactions are rare and occur at similar rates across both medications
